GBA's "2021 Stock Phantasma"

Dear Mr Mizuho.-

I am reminded of what you told me when we first met. If you don't leave a saucer of milk the kitten won't come. You know how this works. Your price target on Marqeta is a foolish move on your part. We all have come to terms with the reliance on Square, there is nothing new there, you avoided the Crypto angle completely. We are very disappointed in your analysis if you can call it that. ~GBA
 
stonedinvestor said:
Dear Mr Mizuho.-

I am reminded of what you told me when we first met. If you don't leave a saucer of milk the kitten won't come. You know how this works. Your price target on Marqeta is a foolish move on your part. We all have come to terms with the reliance on Square, there is nothing new there, you avoided the Crypto angle completely. We are very disappointed in your analysis if you can call it that. ~GBA
More...
What's that about?
Someone downgrade it?

Hey Stoney I have a new one.
IPO.
Biotech.
Hallucinogenics.
Backed by Peter T.

ATAI
$18
German operation.

Peter Thiel-Backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Natan Ponieman, Benzinga
Jun. 18, 2021, 05:02 PM


Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday.

The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sector to IPO this year on the Nasdaq, including MindMed (NASDAQ:MNMD) and Compass Pathways (NASDAQ:CMPS).

Initially founded as a holding group that later became involved in operations, Atai handles a growing portfolio of about 12 companies, all focused on bringing novel mental health treatments through the use of various disruptive technologies and molecules including psychedelic medicines.

Its portfolio includes Perception Neurosciences, a company putting ketamine through clinical trials for the treatment of depression, as well as other companies developing psychedelics like MDMA, ibogaine and DMT for mental health purposes.

Atai is also a major shareholder in Compass Pathways, a company developing psilocybin products for psychedelics-assisted psychotherapy, which was the first psychedelics company to debut on Wall Street in September 2020.
 
You must log in or register to reply here.
Back
Top